Trial Profile
Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Narsoplimab (Primary)
- Indications Thrombotic microangiopathy
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 18 Dec 2019 According to an Omeros Corporation media release, myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab.
- 17 May 2017 According to an Omeros Corporation media release, the company has established a compassionate-use program for OMS721, which is active in both the U.S. and Europe.
- 10 Feb 2015 New trial record